Outcome of Board meeting held on May 30, 2025 Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.6 pts less than Nifty Microcap 250 and 12.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories' board approved audited financial results for Q4 and FY ended March 31, 2025, with the statutory auditor (M.A. Parekh & Associates) issuing an unmodified opinion. Revenue from operations jumped about 37% year-on-year to ₹11,500.53 lakhs (vs ₹8,366.04 lakhs in FY24), while net profit rose roughly 53% to ₹2,415.56 lakhs (vs ₹1,578.90 lakhs). EPS climbed to ₹67.61 from ₹44.19. The board recommended a 15% final dividend (₹1.50 per share on face value of ₹10), subject to shareholder approval. It also appointed M/s SARK & Associates LLP as secretarial auditor for five years (FY26–FY30), M/s S K Doshi & Associates as internal auditor for FY26, and M/s Aatish Dhatrak & Associates as cost auditor for FY26. Q4 standalone profit came in lower at ₹282.71 lakhs partly due to an exceptional item of ₹76.96 lakhs (provision for income tax of an earlier year).
Strong full-year revenue and profit growth along with a dividend announcement are positive signals for shareholders. The continued unmodified audit opinion and reappointment of auditors point to stable governance, though the sharp Q4 dip warrants a closer look at quarterly trends.